CN114644655B - 一种光催化磷酰化喹唑啉酮类化合物的制备方法 - Google Patents
一种光催化磷酰化喹唑啉酮类化合物的制备方法 Download PDFInfo
- Publication number
- CN114644655B CN114644655B CN202210408638.3A CN202210408638A CN114644655B CN 114644655 B CN114644655 B CN 114644655B CN 202210408638 A CN202210408638 A CN 202210408638A CN 114644655 B CN114644655 B CN 114644655B
- Authority
- CN
- China
- Prior art keywords
- phosphoryl
- pent
- photosensitizer
- photocatalytic
- quinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 phosphoryl quinazolinone compound Chemical class 0.000 title claims abstract description 42
- 230000001699 photocatalysis Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 12
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical group CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 9
- CPHQIXFHFRXVNK-UHFFFAOYSA-N 3-pent-4-enylquinazolin-4-one Chemical compound C(CCC=C)N1C=NC2=CC=CC=C2C1=O CPHQIXFHFRXVNK-UHFFFAOYSA-N 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 4
- DBZJJPROPLPMSN-UHFFFAOYSA-N bromoeosin Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 DBZJJPROPLPMSN-UHFFFAOYSA-N 0.000 claims description 3
- 238000006352 cycloaddition reaction Methods 0.000 claims description 3
- 229960001483 eosin Drugs 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229910001392 phosphorus oxide Inorganic materials 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007800 oxidant agent Substances 0.000 abstract 2
- 230000001590 oxidative effect Effects 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 238000007146 photocatalysis Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000000758 substrate Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 7
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- VWBYXJRDIQCSLW-UHFFFAOYSA-N O=[P](c1ccccc1)c1ccccc1 Chemical compound O=[P](c1ccccc1)c1ccccc1 VWBYXJRDIQCSLW-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VQQVWGVXDIPORV-UHFFFAOYSA-N Tryptanthrine Chemical compound C1=CC=C2C(=O)N3C4=CC=CC=C4C(=O)C3=NC2=C1 VQQVWGVXDIPORV-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QDWOIMWUGPSJMU-UHFFFAOYSA-N 1-chloro-4-(4-chlorophenyl)phosphonoylbenzene Chemical compound C1=CC(Cl)=CC=C1P(=O)C1=CC=C(Cl)C=C1 QDWOIMWUGPSJMU-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- LRUAHUVWNCLTIQ-UHFFFAOYSA-N 3-(2-prop-1-en-2-ylphenyl)quinazolin-4-one Chemical compound C=C(C)C1=C(C=CC=C1)N1C=NC2=CC=CC=C2C1=O LRUAHUVWNCLTIQ-UHFFFAOYSA-N 0.000 description 1
- XPYNQLLBWVASGN-UHFFFAOYSA-N CC(C=C12)=CC=C1N=CN(CCCC=C)C2=O Chemical compound CC(C=C12)=CC=C1N=CN(CCCC=C)C2=O XPYNQLLBWVASGN-UHFFFAOYSA-N 0.000 description 1
- YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于氮杂环合成技术领域,具体公开了一种光催化制备磷酰化喹唑啉酮类化合物的方法,是在空气环境中,将3‑(戊‑4‑烯‑1‑基)喹唑啉‑4(3H)‑酮类化合物和芳基磷氧类化合物溶于溶剂中,在光敏剂和可见光照射作用下,使3‑(戊‑4‑烯‑1‑基)喹唑啉‑4(3H)‑酮类化合物的末端非活化烯烃与芳基磷氧自由基环加成,生成磷酰化喹唑啉酮类化合物。本方法的光敏剂廉价,无额外氧化剂的参与(空气中的氧气作为氧化剂),环境友好,原子经济性高且后处理简便。本方法在药物合成领域具有广阔的应用前景。
Description
技术领域
本发明属于氮杂环合成以及光催化有机合成领域,涉及一种喹唑啉酮类化合物的制备,具体涉及一种廉价光敏剂参与的磷酰化喹唑啉酮类化合物的制备方法。
背景技术
目前,可见光介导作为一种强大的合成手段,可实现具有挑战性的化学转化,因此备受有机合成家们的关注,其次其作为一种广泛的清洁能源也受到化学各领域科学家们的关注。近些年,可见光诱导的合成方法被广泛用于合成有机小分子过程中,因其可见光作为反应驱动力,完全符合绿色化学的发展需求。可见光催化通常在温和的条件下进行,操作简便。有机化学领域中,通过可见光氧化还原反应合成新型化合物已成为一种重要的合成策略。由于底物分子通过外层单电子转移形成高活性自由基参与反应,该策略可以为许多难以通过离子型反应直接获得的重要化合物提供直接、高效的合成途径。这些反应条件温和、回收率高、选择性好、底物官能团耐受性高等特点。
喹唑啉酮作为一类具有良好生物医药活性的含氮杂环化合物,是150多种生物碱的重要母核结构。很多天然产物、药物活性分子的结构单元中也存在喹唑啉酮结构,如色胺酮、骆驼宁碱A等生物碱都是具有喹唑啉酮类骨架结构。喹唑啉酮还是精细化工和医药合成的重要中间体,如由喹唑啉酮经氯化、氨化后得到的4-氨基喹唑啉是一系列药物的基本骨架。喹唑啉酮及其衍生物在杀菌、消炎、止痛、抗高血压、抗糖尿病、抗疟疾、抗癌等方面均显示出良好的生物活性,如用于疟疾的常山碱、用于安眠药的安眠酮、抗高血压药多沙唑嗪等。因喹唑啉酮类化合物独特的结构特征、广泛的功能基团和广谱的生物活性,引起合成化学家的广泛兴趣。
喹唑啉及其衍生物的典型制备方法是在氨存在下加热2-酰基-N-酰苯胺,此种生产方法污染较多,实验过程中危险系数较大。因此,开发新型喹唑啉酮化合物合成方法具有重要的实用价值。目前,国内外还没有利用可见光催化磷酰化喹唑啉酮类化合物的公开文献。
发明内容
本发明的目的在于,提供一种光催化磷酰化喹唑啉酮类化合物的制备方法。该方法是在空气气氛、室温环境下,以清洁能源可见光的照射为驱动力,使3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物的末端非活化烯烃与芳基磷氧自由基环加成生成所需的磷酰化喹唑啉酮类化合物。
为实现上述目的,本发明采用的技术方案为:一种光催化磷酰化喹唑啉酮类化合物的制备方法,其特征在于:该方法是在空气环境中,将3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物与芳基磷氧类化合物溶于溶剂中,在光敏剂和可见光照射作用下,使3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物的末端非活化烯烃与芳基磷氧自由基环加成,生成磷酰化喹唑啉酮类化合物,反应通式如下:
其中,3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物通式中,R1为氢、Me、NHBoc或CF3,芳基磷氧类化合物通式/>中,R2为苯基、甲氧基苯基或卤素苯基。
较佳的,上述光敏剂为四溴荧光素(EosinY);可见光照射波长为450nm;溶剂为2-甲基四氢呋喃;反应温度为室温,时长为12h;反应初始时3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮:芳基磷氧类化合物:光敏剂的摩尔比为2:4:0.1。
本发明提供了一种经济、高效的磷酰化喹唑啉酮类化合物合成方法,本方法在可见光照射且廉价光敏剂条件下,3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物与芳基磷氧类化合物通过自由基环加成途径,以制备磷酰化喹唑啉酮类化合物。本发明方法涉及未活化末端烯烃双功能化和自由基途径,包括芳基磷氧自由基生成、四溴荧光素发生基态—激发态—自由基阴离子—基态循环、超氧根阴离子(O2 ·-)的形成。本发明的方法原料合成简单,反应高效,具有良好的底物适应性、廉价的光敏剂催化、外加添加剂的参与的特点。
具体实施方式
下列实施例将有助于理解本发明,但本发明的内容并不局限于此。
实施例1
室温下,将底物3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮42.8毫克(0.2mmo l)和二苯基磷氧80.8毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得66.3毫克黄色固体,产率为80%,经鉴定,其结构式为:表征数据如下:
1H NMR(400MHz,CDCl3):δ8.22(dd,J=8.0,1.2Hz,1H),7.96–7.90(m,2H),7.81–7.75(m,2H),7.71–7.66(m,1H),7.55–7.40(m,8H),4.25–4.18(m,1H),3.93–3.86(m,1H),3.78–3.70(m,1H),3.38–3.27(m,1H),2.56–2.45(m,2H),1.97–1.88(m,2H),1.76–1.69(m,1H);
13C NMR(101MHz,CDCl3):δ162.11,156.51(d,J=13.2Hz,1C),147.05,134.14,133.30(dd,J=163.6,99.8Hz,1C),131.97(dd,J=17.3,2.7Hz,1C)131.16(d,J=9.3Hz,1C),130.67(d,J=9.5Hz,1C),129.87(dd,J=14.7,11.8Hz,1C),126.86(d,J=13.6Hz,1C),126.49,120.31,41.60,36.00(d,J=1.4Hz,1C),32.26(d,J=72.4Hz,1C),26.85(d,J=1.9Hz,1C),20.90;
31P NMR(162MHz,CDCl3):δ32.49;HRMS(ESI)m/z calcd.for C25H23N2NaO2P[M+Na]+:437.1389,found 437.1395。
实施例2
室温下,将底物6-甲基-3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮45.6毫克(0.2mmol)和二苯基磷氧80.8毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得54.8毫克白色固体,产率为64%。
该固体经鉴定,结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.02–7.98(m,1H),7.94–7.90(m,2H),7.80–7.75(m,2H),7.52–7.46(m,5H),7.45–7.41(m,3H),4.23–4.17(m,1H),3.90–3.84(m,1H),3.73(ddd,J=15.5,9.4,3.0Hz,1H),3.90–3.84(m,1H),2.57–2.49(m,1H),2.49–2.42(m,4H),1.97–1.85(m,2H),1.74–1.66(m,1H);
13C NMR(126MHz,CDCl3):δ162.06,155.57(d,J=13.0Hz),145.04,136.56,135.60,134.56(dd,J=200.7,99.8Hz),132.00(dd,J=19.9,2.7Hz),131.16(d,J=9.4Hz),130.67(d,J=9.5Hz),128.84(dd,J=16.0,11.8Hz),126.40(d,J=73.4Hz),120.00,41.50,35.82(d,J=1.5Hz),32.67(d,J=72.3Hz),26.82(d,J=2.0Hz),21.38,20.89;
31P NMR(202MHz,CDCl3):δ32.97;HRMS(ESI)m/z calcd.for C26H25N2NaO2P[M+Na]+:451.1546,found 451.1549。
实施例3
室温下,将底物(4-氧代-3-(戊-4-烯-1-基)-3,4-二氢喹唑啉-6-基)氨基甲酸叔丁酯65.8毫克(0.2mmol)和二苯基磷氧80.8毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1)得76.2毫克白色固体,产率为73%。
经鉴定,该固体结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.15(s,1H),8.01(d,J=2.6Hz,1H),7.96–7.89(m,2H),7.81–7.74(m,2H),7.55–7.47(m,5H),7.46–7.42(m,2H),7.28(s,1H),4.26–4.21(m,1H),3.92–3.86(m,1H),3.73(ddd,J=15.5,9.3,2.9Hz,1H),3.34–3.27(m,1H),2.53–2.46(m,2H),1.98–1.88(m,2H),1.75–1.69(m,1H),1.53(s,9H);
13C NMR(126MHz,CDCl3):δ161.88,154.87(d,J=13.3Hz,1C),152.94,142.82,137.46,133.48(dd,J=206.8,99.5Hz,1C),131.92(dd,J=21.7,2.7Hz,1C),131.18(d,J=9.2Hz,1C),130.68(d,J=9.4Hz,1C),128.86(dd,J=17.6,11.7Hz,1C),127.88,125.65,120.61,80.98,41.60,35.88,32.26(d,J=72.3Hz,1C),28.50,26.92(d,J=1.7Hz,1C),20.97;
31P NMR(202MHz,CDCl3):δ31.94;HRMS(ESI)m/z calcd.for C30H32N3NaO4P[M+Na]+:552.2023,found 552.2025.
实施例4
室温下,将底物3-(戊-4-烯-1-基)-6-(三氟甲基)喹唑啉-4(3H)-酮56.4毫克(0.2mmol)和二苯基磷氧80.8毫克(0.4mmol)、光敏剂EosinY(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得68.5毫克白色固体,产率为71%。
经鉴定,该固体结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.51(s,1H),7.93–7.85(m,3H),7.79–7.71(m,3H),7.54–7.48(m,3H),7.46–7.40(m,2H),7.32(dt,J=7.5,3..0Hz,1H),4.25–4.19(m,1H),3.94–3.89(m,1H),3.68(ddd,J=15.4,9.6,3.2Hz,1H),3.42–3.33(m,1H),2.61–2.53(m,1H),2.50–2.44(m,1H),2.00–1.91(m,2H),1.79–1.71(m,1H);
13C NMR(126MHz,CDCl3):δ161.37,158.92(d,J=12.4Hz,1C),149.13,133.20(d,J=182.2,99.3Hz,1C),132.07(dd,J=19.6,2.7Hz,1C),131.67,131.12(d,J=9.4Hz,1C),130.68(d,J=9.5Hz,1C),130.22,130.19,128.92(dd,J=16.3,11.9Hz,1C),127.91,120.13,41.85,36.24(d,J=1.6Hz,1C),32.18(d,J=72.1Hz,1C),26.69(d,J=2.2Hz,1C),20.81;
19F NMR(471MHz,CDCl3):δ-62.26.;
31P NMR(202MHz,CDCl3):δ32.29;HRMS(ESI)m/z calcd.for C26H22F3N2NaO2P[M+Na]+:505.1263,found 505.1269。
实施例5
室温下,将底物3-(戊-4-烯-1-基)-6-(三氟甲基)喹唑啉-4(3H)-酮40.0毫克(0.2mmol)和二苯基磷氧80.8毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂1,2-二氯乙烷2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得62.4毫克B白色油状液体,产率为78%。
经鉴定,该液体结构式为表征数据如下:
1H NMR(400MHz,CDCl3):δ8.23(d,J=7.9Hz,1H),7.91–7.86(m,2H),7.80(dd,J=11.7,7.3Hz,2H),7.72–7.64(m,2H),7.57–7.40(m,7H),4.29–4.24(m,1H),3.86–3.79(m,1H),3.59–3.48(m,1H),3.46–3.40(m,1H),2.60–2.52(dt,J=15.8,8.7Hz,1H),2.49–2.42(m,1H),2.03–2.02(m,1H);
13C NMR(101MHz,CDCl3):δ160.82,160.61(d,J=16.6Hz,1C),148.91,134.24,132.47(t,J=100.5Hz,1C),132.25(dd,J=12.4,2.5Hz,1C),131.05(d,J=9.4Hz,1C),130.75(d,J=9.6Hz,1C),128.99(dd,J=19.0,11.8Hz,1C),126.93,126.57(d,J=1.4Hz,1C),120.85,45.03,38.76(d,J=2.4Hz,1C),31.93(d,J=72.4Hz,1C),28.04;
31P NMR(162MHz,CDCl3):δ31.42(d,J=6.9Hz);HRMS(ESI)m/z calcd.forC24H21N2NaO2P[M+Na]+:423.1233,found 423.1335。
实施例6
室温下,将底物3-(2-(丙-1-烯-2-基)苯基)喹唑啉-4(3H)-酮52.4毫克(0.2mmol)和二苯基磷氧80.8毫克(0.4mmol),光敏剂Eosin Y(0.01mmo l)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(乙酸乙酯/石油醚=1/1)得75.8毫克白色固体,产率为74.9%。
经鉴定,该固体结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.35(d,J=8.1Hz,1H),8.20(d,J=8.0Hz,1H),7.63–7.57(m,2H),7.52–7.49(m,2H),7.39–7.35(m,2H),7.31(t,J=1.3Hz,2H),7.26–7.25(m,2H),7.12(dd,J=2.8,2.0Hz,2H),7.05–6.98(m,2H),6.86–6.83(m,2H),3.42(dd,J=15.2,8.5Hz,1H),3.03(dd,J=15.2,12.6Hz,1H),1.60(s,3H);
13C NMR(126MHz,CDCl3):δ162.70(d,J=2.5Hz,1C),159.54,147.17,138.79,133.91,133.35(d,J=2.7Hz,1C),132.54(d,J=2.8Hz,1C),131.27(dd,J=38.5,2.6Hz,1C),130.63(d,J=11.5Hz,1C),130.44(d,J=16.1,9.7Hz,1C),128.86(dd,J=68.8,58.1Hz,1C),128.68,128.45(d,J=11.7Hz,1C),127.77(d,J=11.8Hz,1C),126.62(d,J=10.6Hz,1C),124.52,121.61,116.78,46.26(d,J=4.0Hz,1C),39.70(d,J=70.5Hz,1C),29.64(d,J=12.4Hz,1C);31P NMR(202MHz,CDCl3):δ25.44;
HRMS(ESI)m/z calcd.for C29H23N2NaO2P[M+Na]+:485.1389,found485.1391。
实施例7
室温下,将底物3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮42.8毫克(0.2mmo l)和双(4-甲氧基苯基)氧化磷104.8毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得74.9毫克黄色油状液体,产率为79%。
经鉴定,该液体结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.23(dd,J=8.0,1.6Hz,1H),7.83(dd,J=11.1,8.7Hz,2H),7.72–7.65(m,3H),7.58(d,J=8.2Hz,1H),7.43–7.40(m,1H),6.99(dd,J=8.8,2.2Hz,2H),6.93(dd,J=8.8,2.3Hz,2H),4.23–4.18(m,1H),3.93–3.87(m,1H),3.82(d,J=4.4Hz,6H),3.66(ddd,J=15.5,9.6,2.9Hz,1H),3.34–3.26(m,1H),2.54–2.42(m,2H),1.99–1.87(m,2H),1.77–1.70(m,1H);
13C NMR(126MHz,CDCl3):161.37(dd,J=20.7,2.8Hz,1C),160.99,155.56(d,J=13.2Hz,1C),145.99,132.95,131.92(d,J=10.7Hz,1C),131.43(d,J=10.9Hz,1C),125.72(d,J=16.1Hz,1C),125.29,119.20,113.27(dd,J=21.9,12.7Hz,1C),54.32,40.50,34.93,31.49(d,J=73.1Hz,1C),28.68,25.62,19.74(d,J=9.1Hz,1C);
31P NMR(202MHz,CDCl3):δ33.13;HRMS(ESI)m/z calcd.for C27H27N2NaO4P[M+Na]+:497.1601,found 497.1603。
实施例8
室温下,将底物3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮42.8毫克(0.2mmo l)和双(4-氯苯基)氧化膦108.0毫克(0.4mmol)、光敏剂Eosin Y(0.01mmol)及溶剂2-甲基四氢呋喃2毫升,在空气环境下加入到15毫升封管中。然后将封管放入10瓦450nm光反应器中反应12h。经薄层色谱(TCL)检测直到反应完全,滤液经旋转蒸发后经硅胶柱层析分离(洗脱剂:乙酸乙酯/石油醚=1/1),得68.5毫克白色油状液体,产率为71%。
经鉴定,该液体结构式为表征数据如下:
1H NMR(500MHz,CDCl3):δ8.22(d,J=7.9Hz,1H),7.85(dd,J=11.1,8.2Hz,2H),7.71–7.66(m,3H),7.50–7.46(m,3H),7.43–7.40(m,3H),4.21–4.16(m,1H),3.95–3.90(m,1H),3.70(ddd,J=15.6,9.2,3.0Hz,1H),3.34–3.25(m,1H),2.54–2.43(m,2H),1.99–1.89(m,2H),1.77–1.69(m,1H);
13C NMR(126MHz,CDCl3):162.00,156.09(d,J=12.6Hz,1C),146.84,138.85(dd,J=25.5,3.3Hz,1C),134.21,132.51(d,J=10.2Hz,1C),131.97(d,J=10.3Hz,1C),129.41(d,J=12.4Hz,1C),129.26(d,J=12.4Hz,1C),126.82,126.67(d,J=13.1Hz,1C)120.25,41.68,35.87(d,J=1.5Hz,1C),32.30(d,J=73.2Hz,1C),26.97(d,J=1.9Hz,1C),20.88;31P NMR(202MHz,CDCl3):δ31.86;
HRMS(ESI)m/z calcd.for C25H21Cl2N2NaO2P[M+Na]+:505.0610,found505.0611。
Claims (3)
1.一种光催化磷酰化喹唑啉酮类化合物的制备方法,其特征在于:该方法是在空气环境中,将3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物与芳基磷氧类化合物溶于溶剂中,在光敏剂和可见光照射作用下,使3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物的末端非活化烯烃与芳基磷氧自由基环加成,生成磷酰化喹唑啉酮类化合物,反应通式如下:
其中,3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮类化合物通式中,R1为H、Me、NHBoc或CF3,芳基磷氧类化合物通式/>中,R2为苯基、甲氧基苯基或卤素苯基;
所述光敏剂为四溴荧光素;
所述可见光照射波长为450nm;
所述溶剂为2-甲基四氢呋喃。
2.如权利要求1所述的一种光催化磷酰化喹唑啉酮类化合物的制备方法,其特征在于:所述反应温度为室温。
3.如权利要求1所述的一种光催化磷酰化喹唑啉酮类化合物的制备方法,其特征在于:所述反应初始时3-(戊-4-烯-1-基)喹唑啉-4(3H)-酮:芳基磷氧类化合物:光敏剂的摩尔比为2:4:0.1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210408638.3A CN114644655B (zh) | 2022-04-19 | 2022-04-19 | 一种光催化磷酰化喹唑啉酮类化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210408638.3A CN114644655B (zh) | 2022-04-19 | 2022-04-19 | 一种光催化磷酰化喹唑啉酮类化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114644655A CN114644655A (zh) | 2022-06-21 |
CN114644655B true CN114644655B (zh) | 2023-10-27 |
Family
ID=81996939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210408638.3A Active CN114644655B (zh) | 2022-04-19 | 2022-04-19 | 一种光催化磷酰化喹唑啉酮类化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114644655B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004002214A (ja) * | 2002-04-09 | 2004-01-08 | Otsuka Pharmaceut Factory Inc | ホスホン酸ジエステル誘導体 |
CN103172636A (zh) * | 2013-03-13 | 2013-06-26 | 上海大学 | 吡啶并喹唑啉酮类化合物及其制备方法 |
CN110041367A (zh) * | 2019-05-28 | 2019-07-23 | 郑州大学 | 光催化合成膦酰化二氢异喹啉酮类化合物 |
CN111072720A (zh) * | 2019-12-27 | 2020-04-28 | 扬州大学 | 一种膦酰基亚甲基取代的五元环状化合物的合成方法 |
CN112759591A (zh) * | 2021-01-07 | 2021-05-07 | 浙江工业大学 | 一种全氟烷基取代的多环喹唑啉酮类衍生物的合成方法 |
CN113072581A (zh) * | 2021-03-17 | 2021-07-06 | 扬州大学 | 一种合成多取代的膦酰基1,3-丁二烯类化合物的方法 |
WO2022020730A1 (en) * | 2020-07-24 | 2022-01-27 | Inipharm, Inc. | Quinazolinone hsd17b13 inhibitors and uses thereof |
CN114108013A (zh) * | 2021-12-31 | 2022-03-01 | 江苏信和生物医药有限公司 | 一种三氟甲基取代的多环喹唑啉酮衍生物的电化学合成方法 |
-
2022
- 2022-04-19 CN CN202210408638.3A patent/CN114644655B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004002214A (ja) * | 2002-04-09 | 2004-01-08 | Otsuka Pharmaceut Factory Inc | ホスホン酸ジエステル誘導体 |
CN103172636A (zh) * | 2013-03-13 | 2013-06-26 | 上海大学 | 吡啶并喹唑啉酮类化合物及其制备方法 |
CN110041367A (zh) * | 2019-05-28 | 2019-07-23 | 郑州大学 | 光催化合成膦酰化二氢异喹啉酮类化合物 |
CN111072720A (zh) * | 2019-12-27 | 2020-04-28 | 扬州大学 | 一种膦酰基亚甲基取代的五元环状化合物的合成方法 |
WO2022020730A1 (en) * | 2020-07-24 | 2022-01-27 | Inipharm, Inc. | Quinazolinone hsd17b13 inhibitors and uses thereof |
CN112759591A (zh) * | 2021-01-07 | 2021-05-07 | 浙江工业大学 | 一种全氟烷基取代的多环喹唑啉酮类衍生物的合成方法 |
CN113072581A (zh) * | 2021-03-17 | 2021-07-06 | 扬州大学 | 一种合成多取代的膦酰基1,3-丁二烯类化合物的方法 |
CN114108013A (zh) * | 2021-12-31 | 2022-03-01 | 江苏信和生物医药有限公司 | 一种三氟甲基取代的多环喹唑啉酮衍生物的电化学合成方法 |
Non-Patent Citations (8)
Title |
---|
Peroxide-Mediated Oxidative Radical Cyclization to the Quinazolinone System: Efficient Syntheses of Deoxyvasicinone, Mackinazolinone and (±)-Leucomidine C;Jazmín García-Ramírez等;Synthesis;第52卷;A–G * |
Photoaddition of 4(3H)-quinazolinone derivatives to olefins: effects of the 2-substituent;Chikark Kaneno等;Chem. Pharm. Bull.;第34卷(第9期);3672-3681 * |
Photoinduced homolytic decarboxylative acylation/cyclization of unactivated alkenes with a-keto acid under external oxidant and photocatalyst free conditions: access to quinazolinone derivatives;Bin Sun等;Chem. Commun.;第57卷;6050-6053 * |
Photo-triggered self-catalyzed fluoroalkylation/cyclization of unactivated alkenes: synthesis of quinazolinones containing the CF2R group;Jin Yang等;Green Chem.;第23卷;575-581 * |
Reductive cyclisations of amidines involving aminal radicals;Huan-Ming Huang等;Chem. Commun.;第54卷;10160-10163 * |
Self-Catalyzed Phototandem Perfluoroalkylation/Cyclization of Unactivated Alkenes: Synthesis of Perfluoroalkyl-Substituted Quinazolinones;Bin Sun等;Org. Lett.;第23卷;1026-1031 * |
Visible-Light Photoredox Catalyzed Oxidative/Reductive Cyclization Reaction of N‑Cyanamide Alkenes for the Synthesis of Sulfonated Quinazolinones;Ping Qian等;Org. Lett.;第19卷;4798-4801 * |
Visible-Light Photosynthesis of CHF2/CClF2/CBrF2-Substituted Ringfused Quinazolinones in Dimethyl Carbonate;Qing-Wen Gui等;Chem Asian J.;第17卷;1-4 * |
Also Published As
Publication number | Publication date |
---|---|
CN114644655A (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Metal-free visible-light-initiated direct C3 alkylation of quinoxalin-2 (1 H)-ones and coumarins with unactivated alkyl iodides | |
Falkowski et al. | Metal‐Organic Frameworks as Single‐Site Solid Catalysts for Asymmetric Reactions | |
Li et al. | Synthesis of 8-Alkoxy-5 H-isochromeno [3, 4-c] isoquinolines and 1-Alkoxy-4-arylisoquinolin-3-ols through Rh (III)-Catalyzed C–H Functionalization of Benzimidates with 4-Diazoisochroman-3-imines and 4-Diazoisoquinolin-3-ones | |
CN107602577A (zh) | 手性桥环骨架羟吲哚螺哌啶类化合物及其合成方法 | |
CN112574138A (zh) | 一种利用光催化微通道制备α,α-氟苄基酮类化合物的方法 | |
CN111410637A (zh) | 一种利用微流场光催化反应技术制备含芳杂基的α-羰基类化合物的方法 | |
CN111072720B (zh) | 一种膦酰基亚甲基取代的五元环状化合物的合成方法 | |
CN112979644A (zh) | 一种利用光催化微通道制备氟甲基化吲哚[2,1,a]异喹啉衍生物的方法 | |
CN112441875B (zh) | 一种铜光催化合成9-三氟甲基-9,10-二氢菲类化合物的方法 | |
CN114644655B (zh) | 一种光催化磷酰化喹唑啉酮类化合物的制备方法 | |
CN114591344A (zh) | 一种手性螺环四氢呋喃-吡唑啉酮化合物的合成方法 | |
CN110252351B (zh) | 铜催化剂在催化1-吡啶基吲哚化合物、亚硝酸叔丁酯反应中的应用 | |
CN114436936B (zh) | 一种通过微流场可见光催化反应技术连续化制备丙二烯类化合物的方法 | |
CN111875549B (zh) | 一种在水相中光催化合成喹唑啉酮化合物的方法 | |
CN112430206B (zh) | 一种手性/消旋6-取代吲哚类化合物的制备方法 | |
Kanta Das et al. | One‐Pot Manganese (I)‐Catalyzed Oxidant‐Controlled Divergent Functionalization of 2‐Arylindazoles | |
Cecconi et al. | Opening of the P4 molecule: preparation and crystal structure of a cobalt complex of an. eta. 4-tetraphosphabutadiene ligand | |
Kakeshpour et al. | Green Synthesis of Xanthenes: Utilizing Sulfonated Fructose as an Efficient and Eco-friendly Catalyst | |
CN113248422B (zh) | 一种手性α-氮杂芳烃四级碳中心类化合物、其制备方法及应用 | |
CN112441874B (zh) | 一种铱光催化合成9-三氟甲基-9,10-二氢菲类化合物的方法 | |
CN110194760B (zh) | 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法 | |
CN112574251B (zh) | 一种可见光促进1-膦酰基-2-萘酚衍生物的制备方法 | |
CN114591369B (zh) | 一种亚磷酰胺配体及其制备方法、应用 | |
CN114031541B (zh) | 一种2-取代3-甲基吲哚类衍生物的制备方法 | |
CN116283975B (zh) | 一种利用光催化微通道制备烷基化吲哚[2,1,a]异喹啉衍生物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |